Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Accured Expenses (2020 - 2025)

Maxcyte (MXCT) has disclosed Change in Accured Expenses for 6 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 3.61% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.9 million, a 32.35% decrease, with the full-year FY2024 number at -$9000.0, up 76.92% from a year prior.
  • Change in Accured Expenses was $2.0 million for Q3 2025 at Maxcyte, up from -$5.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.5 million in Q4 2021 to a low of -$5.3 million in Q2 2025.
  • A 5-year average of -$22321.1 and a median of $10000.0 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 20670.0% in 2024, then tumbled 2428.91% in 2025.
  • Maxcyte's Change in Accured Expenses stood at $2.5 million in 2021, then tumbled by 61.28% to $976600.0 in 2022, then tumbled by 103.69% to -$36000.0 in 2023, then skyrocketed by 4019.44% to $1.4 million in 2024, then skyrocketed by 41.89% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Change in Accured Expenses are $2.0 million (Q3 2025), -$5.3 million (Q2 2025), and -$4000.0 (Q1 2025).